Background: Lung cancer is the second most incident among men and the fourth among women in Brazil. Data on how it is diagnosed and staged are relatively scarce in Brazil. According Brazilian data published in the last 15 years, NSCLC is the most frequent histological subgroup (80%), being diagnosed, unfortunately, in advanced stage (71% to 94% in stage III and IV). Besides, Brazilian health care system is divided into private and public coverage (27% and 73%, respectively), and there are significant discrepancies in health care resources availability, which may impact on patients' outcome. This study aims to characterize treatment patterns among stage IIIb NSCLC Brazilian patients and their outcomes. Method: In this retrospective cohort study, newly diagnosed (between January and December 2014) advanced NSCLC patients were consecutively included. Data were collected from medical records of 10 Brazilian cancer institutions and recorded in electronic clinical report form. Demographic data, medical history, tumor staging, pathological characteristics, treatments and outcomes were collected and analyzed. For each patient, maximum follow-up was 36 months. Results: 391 patients from 8 different Brazilian states were enrolled, 69 (17.6%) had stage IIIb disease and were the focus of this analysis. 48 were men (69.6%), median age was 64 years, 85.5% have been treated in public and 14.5% in private health system; 82.6% were former or current smokers. The most frequent histological subtypes were squamous cell carcinoma (SqCC) with 32 cases (46.4%) and adenocarcinoma (ADC) with 30 (43.5%). Among smokers, 45.6% had ADC and 43.9% SqCC. At diagnosis, WHO-PS 0, 1, 2, 3, and unknown status were 5.8%, 40.6%, 21.7%, 15.9%, and 15.9%, respectively. Initial treatment according to health systems is described in Table 1 . Median overall survival observed in overall group was 9.4 months (CI95% 6.6-12.1). Table1 Background: Timely access of patients to cancer care is a major factor influencing treatment initiation. There is limited data on waiting times to lung cancer diagnosis and treatments in Latin-America. In Argentina, oncological care is provided mainly in public and private hospitals. In this study, we describe and compare the time elapsed from the first consultation to the diagnosis and treatment of patients with nonesmall cell lung cancer (NSCLC) treated with chemotherapy at public and private academic hospitals in Buenos Aires. We also describe and correlate social, economic and educational factors that could have an effect on the time to treatment as a surrogate of patient's access. Method: Multicenter, retrospective cohort study. Patients >18 years old with diagnosis of NSCLC treated with chemotherapy were included. Clinical and epidemiological data were collected. Kaplan-Meier method was used to study time intervals from first consultation to diagnosis and treatment; and the log rank test for comparisons between public and private hospitals. We performed multivariate analysis (Cox Regression Models) to study the correlation between social, economic and educational factors and the time to therapy. Results: Between 06/ 2016 and 09/2017, 100 patients with NSCLC were included, 41 in Public Hospitals (PuH) and 59 in Private Hospitals (PrH). Median age (IQR) was 65 years (58-71), male individuals (PuH/PrH): 63.4%/ 59.3%. There were no significant differences in smoking habits between groups. Stage (I/II/III/IV/Relapse), PuH: 2.4%/7.3%/17.1%/ 70.7%/2.5%; PrH: 0%/10.2%/ 30.5%/57.6%/1.7%. Chemotherapy treatment for metastatic disease (PuH/PrH): 73.2%/55.9%, adjuvant chemotherapy (PuH/PrH): 9.8%/11.9%, chemoradiation therapy (PuH/PrH): 12.2%/32.2%. Adenocarcinoma histology (PuH/PrH/): 61%/83%, squamous cell carcinoma (PuH/PrH): 31.7%/13.6%. Median (IQR) time interval between the first consultation and diagnosis was 86 days (69-116) in PuH and 48 days (33-61) in PrH (p¼0.0014). Globally, median (IQR) time elapsed between diagnosis and treatment with chemotherapy was 71 (60-83) days in 
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Histology was e neuroendocrine tumor in 6 (13%), mucoepidermoid carcinoma in 3 (6%), SCC in 4 (8%) and adenocarcinoma in 35 (73%) patients. Baseline features are outlined in Table 1 . Thirty-two (82%) patients had metastasis on diagnosis and 40% (n¼10) patients had ALK-rearranged adenocarcinoma. After median follow-up of 9.6 months (range: 1.1-56.2), median progression-free survival (PFS) was 14.4 months (95 CI: 6.2-35) and median overall survival (OS) was 31.6 months (95 CI: 8.2 e not reached). Median PFS was 8.7 months & 35.5 months whereas median OS was 17.9 months & 56.2 months in patients treated with chemotherapy (n¼16) and with tyrosine kinase-inhibitor (n¼11), respectively. Median PFS was 35.5, 14.4 & 6.2 months whereas median OS was 56.2, not reached & 8.9 months in patients treated with EGFR mutation (n¼5), ALK-rearrangement (n¼9) and molecular negative (n¼11) tumors, respectively. 
